N-[-2-(1-piperidino)ethyl]carbamoylphosphonic acid | 334996-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-[-2-(1-piperidino)ethyl]carbamoylphosphonic acid
• 英文别名: PIP-CPO；N-(2-[1-piperidino]ethyl)phosphonoformamide betaine；hydroxy(2-piperidin-1-ium-1-ylethylcarbamoyl)phosphinate
• CAS: 334996-95-1
• 化学式: C₈H₁₇N₂O₄P
• 分子量: 236.208
• InChiKey: RYOLSHSTDAURSO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  89.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  在 甲醇 作用下， 生成 N-[-2-(1-piperidino)ethyl]carbamoylphosphonic acid
  参考文献：
  名称：

  Compositions comprising oxophosphonate-based metalloproteinase inhibitors

  摘要：

  本发明涉及用于治疗或控制与含锌蛋白酶，特别是金属蛋白酶相关的疾病状态或病况的组合物。这些组合物中的活性成分是具有化学式(I)的α-氧代或α-硫代膦酸酯。在化学式(I)的膦酸酯中，有些是已知的，而另一些是新的。这些新化合物构成了本发明的另一个方面。

  公开号：

  US07101864B1

文献信息

• COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS
  申请人：Breuer Eli

  公开号：US20060199787A1

  公开（公告）日：2006-09-07

  The present invention relates to compositions useful for treating or controlling disease states or conditions associated with zinc containing proteinases, especially metalloproteinases. The active ingredient in these compositions is an alpha-oxo- or alpha-thioxophosphonate of formula (I). Out of the phosphonates of formula (I), some are known and others are new. The novel compounds constitute another aspect of the invention.

  本发明涉及用于治疗或控制与含锌蛋白酶，特别是金属蛋白酶相关的疾病状态或条件的组合物。这些组合物中的活性成分是公式(I)的α-氧代或α-硫代膦酸酯。在公式(I)的膦酸酯中，有些是已知的，而其他的是新的。新化合物构成了本发明的另一个方面。
• Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells
  作者：Efrat Harel、Abraham Rubinstein、Weibin Chen、Eli Breuer、Boaz Tirosh

  DOI：10.1016/j.bmcl.2010.09.048

  日期：2010.11

  Some carbamoylphosphonates (CPOs) inhibit matrix metalloproteinases (MMPs). Although MMPs are involved in inflammatory processes, the anti-inflammatory activity of CPOs has not been reported. In this context we compared the biological activity of the three aminoCPOs, PYR-CPO, PIP-CPO and cis-ACCP. We were particularly interested in their capability to modulate the secretion of tumor necrosis factor alpha (TNF alpha). LPS-activated mouse peritoneal macrophages and LPS-activated mouse splenocytes were used to explore this question. It was found that the aminoCPOs were able to reduce TNF alpha secretion to a level equivalent to the reduction caused by the steroid drug budesonide (BUD). The reduction in TNF alpha levels was neither accompanied by cytotoxicity, nor did it inhibit cell proliferation. To explicate whether the aminoCPOs affect TNF alpha processing by TNF alpha-converting enzyme (TACE), TACE inhibitory properties of the three molecules was tested in vitro. Only PIP-CPO exerted TACE inhibitory activity at therapeutic (non-cytotoxic) concentrations, indicating on its potential to serve as an anti-inflammatory agent by reducing TNF alpha secretion. (C) 2010 Elsevier Ltd. All rights reserved.
• US7468359B2
  申请人：——

  公开号：US7468359B2

  公开（公告）日：2008-12-23